Starch Sugar Enzymes MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy SourceBy End-use IndustryBy Form

Starch sugar enzymes are industrial biocatalysts, primarily alpha-amylase, beta-amylase and glucoamylase, used to break down starch derived from corn, wheat, cassava and other crops into glucose, maltose and other simple sugars. They are purchased mainly by starch-processing and wet-milling plants, sweetener and syrup manufacturers, brewers and distillers, and bioethanol producers that need to convert raw starch into fermentable or food-grade sugar as an intermediate processing step.

The global starch sugar enzymes market is valued at USD 4.2 billion in 2025 and is set to reach USD 7.64 billion by 2034, a compound annual growth rate of 6.9% across the 2026-2034 forecast period. The study tracks the market across USD 3.05 billion in 2020, USD 3.93 billion in 2024, USD 4.48 billion in 2026 and USD 5.85 billion in 2030.

The type mix shifts over the period. Glucoamylase is the largest line in 2025 at USD 1.848 billion, a 44% share, moving to USD 3.514 billion and 46% by 2034. Other grows fastest at 8.16%, taking its share from 9% to 10%, while Beta Amylase grows slowest at 6.02%. Share moves toward Glucoamylase and Other and away from Alpha Amylase and Beta Amylase, though no line shrinks in revenue terms.

The application split puts Industrial first, at USD 2.856 billion and 68% of revenue in 2025, rising to USD 4.89 billion and 64% in 2034. Specialty grows faster at 9.15% against 6.16%, moving from 24% of revenue to 29% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Asia Pacific is the largest region at 42% of 2025 revenue, worth USD 1.764 billion and reaching USD 3.514 billion by 2034. North America follows at 27%, moving from USD 1.134 billion to USD 1.834 billion, and Middle East and Africa is the smallest at 4%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Coverage extends to five regions, four type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies rather than a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• Revenue grows from USD 4.2 billion in 2025 to USD 7.64 billion in 2034, a compound annual rate of 6.9%, having reached USD 3.93 billion in 2024 from USD 3.05 billion in 2020.
• Glucoamylase is the largest type line at USD 1.848 billion in 2025, a 44% share, reaching USD 3.514 billion and 46% of revenue by 2034.
• Other is the fastest-growing line at 8.16%, lifting its share from 9% in 2025 to 10% in 2034 and its revenue from USD 0.378 billion to USD 0.764 billion.
• Against a base case of USD 7.64 billion in 2034, the study also reports a bear case at USD 6.77 billion and a bull case at USD 8.66 billion, with the assumptions behind each set out separately.
• Asia Pacific holds 42% of global revenue in 2025 at USD 1.764 billion, the largest of the five regions tracked, and reaches USD 3.514 billion by 2034.
• China accounts for 52% of Asia Pacific in the base year, worth USD 0.917 billion in 2025 and reaching USD 1.757 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

The global starch sugar enzymes market is shaped over 2026-2034 by three measurable movements: a change in the type mix, a shift in where revenue sits geographically, and the 6.9% rate carrying the total.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Composition shifts on the type axis. Between 2026 and 2034, 8.16% growth in Other against 6.02% in Beta Amylase pulls the type mix apart. Shares follow: 9% to 10% for Other, 14% to 13% for Beta Amylase. The revenue figures behind that are USD 0.378 billion to USD 0.764 billion and USD 0.588 billion to USD 0.993 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

The regional balance moves. Asia Pacific moves from 42% of revenue in 2025 to 46% in 2034, worth USD 1.764 billion rising to USD 3.514 billion; Latin America moves from 7% of revenue in 2025 to 8% in 2034, worth USD 0.294 billion rising to USD 0.611 billion; Middle East and Africa moves from 4% of revenue in 2025 to 5% in 2034, worth USD 0.168 billion rising to USD 0.382 billion. Against that, North America at 27% moving to 24%, Europe at 20% moving to 17%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Growth compounds at 6.9% without a step change. The market moves through USD 3.05 billion in 2020, USD 3.93 billion in 2024, USD 4.2 billion in 2025, USD 4.48 billion in 2026, USD 5.85 billion in 2030 and USD 7.64 billion in 2034. The forecast rate of 6.9% sits against 6.61% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Growth is concentrated in Other

The 6.9% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

Downside case: USD 6.77 billion rather than USD 7.64 billion by 2034

Upside case: USD 8.66 billion by 2034

Concentration on the type axis

North America holds 27% of the global starch sugar enzymes market in 2025, worth USD 1.134 billion rising to USD 1.834 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share settles at 24% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Glucoamylase largest at 44% of 2025 revenue, Other fastest at 8.16%. The full report breaks North America out along every axis and by country.

85% of North America's base-year revenue comes from the United States; USD 0.964 billion, rising to USD 1.541 billion by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country rather than with a spread of them. Against regional totals of USD 1.134 billion in 2025 and USD 1.834 billion in 2034, it is the country the full report breaks out in detail.

the United States buys along the same lines as the market globally; Glucoamylase first at 44% of 2025 revenue and 46% in 2034, Other fastest at 8.16% on a share moving from 9% to 10%. Its 85% weight in North America means those movements carry straight into the regional totals. Per-type revenue for the United States appears on its own in the full report.

In the United States, enzymes used to convert starch into glucose, dextrose, and other sweeteners are treated as food processing aids or indirect food additives and fall under the oversight of the Food and Drug Administration. A supplier typically establishes safety either through the Generally Recognized As Safe notification pathway or, where that route does not apply, through a formal food additive petition, with the enzyme's source organism, manufacturing process, and purity profile all subject to review. Purity is commonly benchmarked against Food Chemicals Codex specifications, and labelling of downstream food products must identify the enzyme's function where required rather than obscure it as an undisclosed processing aid.

The suppliers tracked in this study (Novozymes A/S, DuPont, BASF SE, DSM-Firmenich, ABF, Advanced Enzymes Technologies, Roquette Freres, Amano Enzyme Inc., Kerry Group plc, Sunson Industry Group Co., Ltd., Specialty Enzymes & Probiotics, Enzyme Development Corporation and Others) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Glucoamylase at 44% of 2025 revenue, and taking Other while it grows at 8.16%. Per-company positioning and share at country level are in the full report only.

Within North America, Canada accounts for 15% of regional revenue and 4.05% of the global total, worth USD 0.17 billion in 2025 and USD 0.293 billion by 2034.

Europe holds 20% of the global starch sugar enzymes market in 2025, worth USD 0.84 billion with USD 1.299 billion projected for 2034. Among the five regions it ranks third by revenue in both years.

17% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Glucoamylase largest at 44% of 2025 revenue, Other fastest at 8.16%. The full report breaks Europe out along every axis and by country.

Germany is the largest market within Europe, generating USD 0.336 billion in 2025 and projected to reach USD 0.494 billion by 2034. Its 40% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 0.84 billion in 2025 and USD 1.299 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Germany is the global one: 44% of 2025 revenue in Glucoamylase, 46% by 2034, against 8.16% growth in Other taking it from 9% to 10%. Its 40% weight in Europe means those movements carry straight into the regional totals. Germany carries its own type breakdown in the full report.

As a European Union member state, Germany applies the EU framework governing food enzymes, under which any enzyme preparation used to break down starch into syrups or sugars must be authorised following a safety evaluation by the European Food Safety Authority before it can appear on the eventual harmonised Union list. Until that list takes full effect, national food law administered through German authorities continues to apply, requiring documentation of the production strain, manufacturing process, and purity criteria. Labelling obligations under the EU Food Information to Consumers Regulation require enzymes to be declared as processing aids or ingredients depending on their carry-over into the finished product, and conformity with these requirements is a precondition for market access.

In Germany the field is Novozymes A/S, DuPont, BASF SE, DSM-Firmenich, ABF, Advanced Enzymes Technologies, Roquette Freres, Amano Enzyme Inc., Kerry Group plc, Sunson Industry Group Co., Ltd., Specialty Enzymes & Probiotics, Enzyme Development Corporation and Others. Glucoamylase, at 44% of 2025 revenue, is where the volume sits, and Other, growing at 8.16%, is where position changes hands over the forecast period.

Within Europe, France accounts for 28% of regional revenue and 5.6% of the global total, worth USD 0.235 billion in 2025 and USD 0.351 billion by 2034.

Asia Pacific holds 42% of the global starch sugar enzymes market in 2025, worth USD 1.764 billion with USD 3.514 billion projected for 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

46% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 6.9% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Glucoamylase leads here as it does globally, at 44% of 2025 revenue, and Other again grows fastest at 8.16%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

52% of Asia Pacific's base-year revenue comes from China; USD 0.917 billion, rising to USD 1.757 billion by 2034. 52% of the region in the base year makes it the largest market here without making it the region. Set against USD 1.764 billion and USD 3.514 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is Glucoamylase at 44% of 2025 revenue, easing to 46% by 2034, and the fastest is Other at 8.16%, from 9% to 10%. Since 52% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. China carries its own type breakdown in the full report.

Food enzymes used in starch-based sugar production in China are regulated as food processing aids under the national food safety standard system overseen by the National Health Commission and enforced by the State Administration for Market Regulation. Enzyme preparations, particularly those derived from newly approved microbial strains, generally require inclusion on the permitted list of food processing aids before commercial use, with evaluation covering the production organism, manufacturing method, and residual purity. Suppliers must ensure conformity with the relevant national food safety standards governing enzyme preparations, maintain traceability of the production strain, and meet labelling and documentation expectations when supplying enzymes into domestic starch-processing and sweetener manufacturing operations.

Competition in China runs between the suppliers this study tracks: Novozymes A/S, DuPont, BASF SE, DSM-Firmenich, ABF, Advanced Enzymes Technologies, Roquette Freres, Amano Enzyme Inc., Kerry Group plc, Sunson Industry Group Co., Ltd., Specialty Enzymes & Probiotics, Enzyme Development Corporation and Others. The commercially relevant division is 44% of 2025 revenue in Glucoamylase, where the volume is, against 8.16% growth in Other, where share moves.

Within Asia Pacific, India accounts for 22% of regional revenue and 9.24% of the global total, worth USD 0.388 billion in 2025 and USD 0.879 billion by 2034.

In Latin America, 7% of global revenue puts 2025 at USD 0.294 billion on the way to USD 0.611 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 8%, at a pace above the 6.9% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Glucoamylase leads here as it does globally, at 44% of 2025 revenue, and Other again grows fastest at 8.16%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

The largest single market in Latin America is Brazil, at USD 0.176 billion in 2025 and USD 0.354 billion in 2034. Carrying 60% of the region in the base year, it sets Latin America's direction rather than contributing to it. Set against USD 0.294 billion and USD 0.611 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Brazil buys along the same lines as the market globally; Glucoamylase first at 44% of 2025 revenue and 46% in 2034, Other fastest at 8.16% on a share moving from 9% to 10%. Because the country carries 60% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by type for Brazil is reported separately in the full report.

In Brazil, food enzymes applied in starch sugar production are regulated as processing aids by the Agência Nacional de Vigilância Sanitária, the national health surveillance authority responsible for food safety. Suppliers are generally required to register enzyme preparations and demonstrate that the production strain, manufacturing process, and purity criteria conform to the applicable technical regulation on enzymes used in food processing. Where an enzyme originates from a genetically modified organism, additional biosafety clearance from the National Technical Biosafety Commission may also be required before commercialisation. Labelling of finished sweetener products must reflect applicable food information rules, and ongoing conformity with registered specifications is expected throughout supply to domestic processors.

The suppliers tracked in this study (Novozymes A/S, DuPont, BASF SE, DSM-Firmenich, ABF, Advanced Enzymes Technologies, Roquette Freres, Amano Enzyme Inc., Kerry Group plc, Sunson Industry Group Co., Ltd., Specialty Enzymes & Probiotics, Enzyme Development Corporation and Others) compete in Brazil across the type lines above. The commercially relevant division is 44% of 2025 revenue in Glucoamylase, where the volume is, against 8.16% growth in Other, where share moves.

Mexico is sized at USD 0.065 billion in 2025, rising to USD 0.141 billion by 2034; 1.55% of global revenue and 22% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 4% of the global starch sugar enzymes market in 2025, worth USD 0.168 billion on the way to USD 0.382 billion by 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Share climbs to 5% by 2034, because it outgrows the market's 6.9%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Glucoamylase largest at 44% of 2025 revenue, Other fastest at 8.16%. Middle East and Africa is reported axis by axis and country by country in the full study.

35% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.059 billion, rising to USD 0.13 billion by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.168 billion to USD 0.382 billion over the same period, and this is the market carrying the country-level detail in the full report.

Saudi Arabia buys along the same lines as the market globally; Glucoamylase first at 44% of 2025 revenue and 46% in 2034, Other fastest at 8.16% on a share moving from 9% to 10%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by type for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, food enzymes used in starch conversion processes fall under the oversight of the Saudi Food and Drug Authority, which aligns its requirements with technical regulations developed through the Gulf Cooperation Council standardisation framework. Suppliers are generally expected to register enzyme preparations and demonstrate that the production organism, manufacturing process, and purity specifications conform to the applicable Gulf or Saudi food safety technical regulation governing processing aids. Halal status is a further consideration relevant to sourcing and certification given the kingdom's regulatory expectations for food ingredients. Labelling and documentation accompanying imported enzyme preparations must support verification by customs and food safety authorities prior to market entry.

Competition in Saudi Arabia runs between the suppliers this study tracks: Novozymes A/S, DuPont, BASF SE, DSM-Firmenich, ABF, Advanced Enzymes Technologies, Roquette Freres, Amano Enzyme Inc., Kerry Group plc, Sunson Industry Group Co., Ltd., Specialty Enzymes & Probiotics, Enzyme Development Corporation and Others. The commercially relevant division is 44% of 2025 revenue in Glucoamylase, where the volume is, against 8.16% growth in Other, where share moves.

Within Middle East and Africa, South Africa accounts for 30% of regional revenue and 1.19% of the global total, worth USD 0.05 billion in 2025 and USD 0.111 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Source, End-Use Industry, Form, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.